CMS Issues Proposed Medicare Part B Drug Payment Model

by Baker Ober Health Law
Contact

On March 11, 2016, CMS published in the Federal Register [PDF] its proposed new Medicare Part B Drug Payment Model. Comments are due by May 9, 2016. Below are some highlights of the proposed rule.

Current Medicare Part B Reimbursement Model

Medicare Part B provides prescription drug coverage to Medicare beneficiaries for drugs that are administered in a physician's office or a hospital outpatient department (such as cancer medications, antibiotic injections, and eye care treatments). Currently, Medicare Part B pays physicians and outpatient departments the average sales price (ASP) of the drug plus a 6-percent add-on.

According to CMS, the current payment model can penalize doctors for prescribing inexpensive, yet more effective drugs, as the 6-percent add-on generates more revenue for more expensive drugs. Therefore, the proposed payment model will test whether lowering the add-on percentage to 2.5 percent but adding a flat fee payment of 16.80 per drug per day will change prescribing incentives and lead to improving quality and value.

CMS says its intent is to "encourage better care, smarter spending, and healthier people by paying providers for what works, unlocking health care data, and finding new ways to coordinate and integrate care to improve quality." 81 Fed. Reg. 13,230, 13,231 (March 11, 2016).

The Proposed Model

CMS will test its proposed model in two phases by placing all providers and suppliers billing for Part B drugs in control or study groups based on selected geographic areas (Primary Care Service Areas). Phase 1 will focus on testing changes to Medicare Part B ASP payments, and Phase 2 will later introduce value-based pricing strategies to further evaluate changes and to collect additional data. This complete evaluation will be conducted over the course of five years, with the goal of having Phase 2 fully operational during the last three years.

Phase 1: Average Sales Price Payments

Beginning no earlier than 60 days after the final rule is published, CMS will test the changes to Medicare Part B ASP payments for drugs by creating the two groups: (1) a control group of physicians and outpatient departments that will be reimbursed under the current 6-percent add-on payment model; and (2) a study group, consisting of different physicians and outpatient departments, that will be reimbursed under the proposed payment model – 2.5 percent of ASP of the drug plus a $16.80 flat payment per drug per day.

Phase 2: Incentive and Value-Based Purchasing Tests

No earlier than January 2017, CMS will begin to test value-based purchasing arrangements, similar to those used by commercial health plans, pharmacy benefit managers, and hospitals, by further dividing the average sales price study and control groups and introducing value-based purchasing tools into the study groups. By introducing these value-based pricing strategies, CMS seeks to test approaches for transition from a volume-based payment system into one that "encourages or even rewards providers and suppliers who maintain or achieve better patient outcomes while lowering Part B expenditures." 81 Fed. Reg. at 13,243.

The proposed value-based pricing strategies/tests include:

  1. Discounting or eliminating patient cost-sharing, which will decrease or eliminate cost sharing for products determined to be high in value.
  2. Feedback on prescribing patterns and online decision support tools, which will create evidence-based clinical decision support tools as a resource for providers.
  3. Indications-based pricing, which will vary the payment for a drug based on its clinical effectiveness for different conditions.
  4. Reference pricing, which will test the practice of setting a standard rate for a group of therapeutically similar drug products.
  5. Risk-sharing agreements based on outcomes, which will allow CMS to enter into voluntary agreements with drug manufacturers to link patient outcomes with payment. This method is sometimes used in the private sector when there are limited published studies about a drug's long-term value with regard to patient health outcomes.

CMS will determine whether the proposed model will reduce Medicare spending, without limiting coverage or benefits, while maintaining or improving patient care. It will do this, in part, by utilizing a concurrent real-time claims monitoring program to track utilization, spending, and prescribing patterns while providing Medicare beneficiaries with access to the same drugs and choice of providers.

Proposed Pre-Appeals Payment Exception

The proposed model introduces a new pre-appeals payment exceptions review process for Phase II that would allow a physician, supplier, or beneficiary to seek an exception from this pricing approach by explaining why Medicare's value pricing policy is not appropriate for the beneficiary.

Additional Comments Solicited

In addition to soliciting comments associated with Phase I and Phase II, CMS is also soliciting comments on (1) how to create value-based purchasing arrangements with manufacturers under Medicare fee-for-service (FFS) payment for drugs; (2) whether CMS should consider updating the Competitive Acquisition Program; and (3) whether CMS should move from a FFS structure to a more bundled or episode-based approach. These additional comments will be considered for future rulemaking.

Ober|Kaler's Comments

By shifting Medicare payments from hospitals and specialties that use higher cost drugs to those that use lower cost drugs, the proposed change will unquestionably be controversial. Providers and suppliers should submit comments to the extent they believe CMS failed to consider important factors in its analysis.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Baker Ober Health Law | Attorney Advertising

Written by:

Baker Ober Health Law
Contact
more
less

Baker Ober Health Law on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.